Semzuvolimab
Semzuvolimab is an experimental cancer drug developed by Innovent Biologics and Eli Lilly and Company. It is a monoclonal antibody designed to inhibit PD-1, a protein that plays a major role in suppressing the immune system. By blocking PD-1, semzuvolimab may help the immune system recognize and attack cancer cells.
Development and Clinical Trials[edit | edit source]
Semzuvolimab is currently in clinical trials for the treatment of various types of cancer. In a Phase 1 trial, the drug showed promising results in patients with advanced solid tumors. The trial found that semzuvolimab was well-tolerated and demonstrated anti-tumor activity.
Innovent and Eli Lilly are also conducting a Phase 3 trial to evaluate the efficacy and safety of semzuvolimab in combination with chemotherapy in patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
Mechanism of Action[edit | edit source]
Semzuvolimab works by binding to PD-1, a protein found on the surface of certain immune cells. PD-1 acts as a "brake" on the immune system, preventing it from attacking normal cells. However, some cancer cells can exploit this mechanism to avoid being targeted by the immune system. By blocking PD-1, semzuvolimab can potentially enhance the body's immune response against cancer cells.
Potential Side Effects[edit | edit source]
As with any drug, semzuvolimab may cause side effects. In clinical trials, the most common side effects were fatigue, decreased appetite, and nausea. Serious side effects, including immune-related adverse events, were also reported.
Future Prospects[edit | edit source]
If successful in clinical trials, semzuvolimab could offer a new treatment option for patients with advanced cancers. However, further research is needed to fully understand the drug's efficacy and safety profile.
Semzuvolimab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD